Equipalazone® 1 g Oral Powder is indicated in the treatment of musculoskeletal disorders in horses and ponies where the anti-inflammatory and analgesic properties of phenylbutazone can offer relief, for example, in lameness associated with osteoarthritic conditions, acute and chronic laminitis, bursitis and carpitis, and in the reduction of post-surgical soft tissue reaction.



Oral administration only.

Usage Details

Horses 450 kg (1000 lb) body weight: Two sachets to be administered twice on day one (equivalent to 8.8 mg/kg/day) followed by one sachet twice daily for four days (4.4 mg/kg/day), then one sachet daily or on alternate days sufficient to keep the horse comfortable (2.2 mg/kg/day).

Ponies 225 kg (500 lb) body weight: One sachet (4.4 mg/kg/day) on alternate days. Adjust dose according to body weight. Discontinue treatment if no response is evident after four to five days treatment. Equipalazone 1 g Oral Powder should be mixed with a small quantity of feed.


  • Not to be used in horses intended for human consumption.
  • Treated horses may never be slaughtered for human consumption.
  • The horse must have been declared as not intended for human consumption under national horse passport legislation.
  • The therapeutic index of phenylbutazone is low.
  • Do not exceed the stated dose or the duration of treatment.
  • Do not use in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
  • Do not administer other NSAIDs concurrently or within 24 hours of each other.
  • Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.
  • Use in any animal less than six weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a risk of increased toxicity.
  • Concurrent administration of potentially nephrotoxic drugs should be avoided.
  • It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered.
  • Gastrointestinal tract ulceration may be exacerbated by corticosteroids in animals given NSAIDs.
  • Use during pregnancy should be avoided whenever possible, particularly during the first trimester.
  • Response to long-term therapy should be monitored at regular intervals by a veterinary practitioner.
  • The product should be handled with care at all times to reduce the risk of accidental ingestion, skin contact or dust inhalation. If accidental skin or eye contact occurs, the site should be washed immediately with water. If the product is ingested, seek medical advice immediately and show the product packaging.
  • Advice to doctors: gastric lavage (emesis in children) should be performed urgently. Charcoal haemoperfusion has also been shown to be beneficial.
  • Treatment should then be administered symptomatically.